WHO Drug Information Vol. 32, No. 4, 2018

ATC/DDD classification

The Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD) as a measuring unit are tools for exchanging and comparing data on drug use at international, national or local levels. The ATC/ DDD system has become the gold standard for international drug utilization research. It is maintained by the WHO Collaborating Centre for Drug Statistics Methodology in Oslo, Norway. Visit www.whocc.no/ for more information.

ATC/DDD classification (temporary)

The following ATC codes and DDDs were agreed at the meeting of the WHO International Working Group for Drug Statistics Methodology in October 2018.

Comments or objections to the decisions from the meeting should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology before 1 February 2019. If no objections are received before this date, the new ATC codes and DDDs will be considered final and included in the January 2020 version of the ATC/DDD Index.

New ATC 5th level codes ATC level name/INN ATC code acalabrutinib L01XE51 amenamevir J05AX26 amlodipine and celecoxib C08CA51 arginine and lysine V03AF11 atorvastatin and omega-3 fatty acids C10BA08 baloxavir marboxil J05AX25 betrixaban B01AF04 brolucizumab S01LA06 cemiplimab L01XC33 crizanlizumab B06AX01 daclatasvir, asunaprevir and beclabuvir J05AP58 darolutamide L02BB06 elagolix H01CC03 elbasvir J05AP10 entinostat L01XX64 Continued

5 51 ATC/DDD classification WHO Drug Information Vol. 32, No. 4, 2018

New ATC 5th level codes (continued)

ATC level name/INN ATC code enviomycin J04AB06 esketamine N06AX271) favipiravir J05AX27 ferrous sodium citrate B03AA12 fimasartan and amlodipine C09DB09 fremanezumab N02CX09 gilteritinib L01XE54 glasdegib L01XX63 glycopyrronium D11AA01 grazoprevir J05AP11 imlifidase L04AA41 inotersen N07XX15 irbesartan, amlodipine and hydrochlorothiazide C09DX07 ivosidenib L01XX62 lamivudine and dolutegravir J05AR25 laninamivir J05AH04 larotrectinib L01XE53 latanoprost and netarsudil S01EE51 latanoprostene bunod S01EE06 luspatercept B03XA06 methionine (11C) V09IX13 mosapride A03FA09 moxidectin P02CX03 opinercept L04AB07 pegvaliase A16AB19 perindopril, bisoprolol and amlodipine C09BX04 plazomicin J01GB14 quizartinib L01XE52 rabeprazole, amoxicillin and clarithromycin A02BD12 Continued

5 52 WHO Drug Information Vol. 32, No. 4, 2018 ATC/DDD classification

New ATC 5th level codes (continued)

ATC level name/INN ATC code rabeprazole, amoxicillin and metronidazole A02BD13 ravulizumab L04AA43 rifamycin A07AA13 risankizumab L04AC18 rosuvastatin and fimasartan C10BX16 rosuvastatin and omega-3 fatty acids C10BA07 siponimod L04AA42 solriamfetol N06BA14 sotagliflozin A10BK06 tafenoquine P01BA07 tamsulosin and tadalafil G04CA54 tecovirimat J05AX24 ulinastatin B02AB05 vancomycin S01AA28 vonoprazan, amoxicillin and clarithromycin A02BD14 vonoprazan, amoxicillin and metronidazole A02BD15

1 Nasal formulations indicated for major depressive disorders. Parenteral formulations are classified in N01AX14

5 53 ATC/DDD classification WHO Drug Information Vol. 32, No. 4, 2018

New ATC level codes (other than 5th levels): Other hematological agents B06AX

Changes of ATC level names

Previous New ATC code lactobacillus fermentum lactobacillus G01AX14 microspheres of human perflutren, human albumin microspheres V08DA01 albumin microspheres of perflutren, phospholipid microspheres V08DA04 phospholipids perflubutane polymer perflubutane, phospholipid microspheres V08DA06 microspheres sulfur hexafluoride sulfur hexafluoride, phospholipid V08DA05 microspheres

New DDDs ATC level name/INN DDD unit Adm.R* ATC code amenamevir 0.4 g O J05AX26 apalutamide 0.24 g O L02BB05 asunaprevir 0.2 g O J05AP06 brodalumab 15 mg P L04AC12 calcium aminosalicylate 15 g O J04AA03 cerliponase alfa 21 mg P A16AB17 elbasvir 50 mg O J05AP10 enviomycin 1 g P J04AB06 erenumab 2.5 mg P N02CX07 favipiravir 1.6 g O J05AX27 glycerol phenylbutyrate 15 g O A16AX09 grazoprevir 0.1 g O J05AP11 laninamivir 40 mg Inhal.powder J05AH04 levofloxacin 0.24 g Inhal.solution J01MA12 nabilone 3 mg O A04AD11 Continued

554 WHO Drug Information Vol. 32, No. 4, 2018 ATC/DDD classification

New DDDs (continued)

ATC level name/INN DDD unit Adm.R* ATC code opinercept 7 mg P L04AB07 pentosan polysulfate sodium 0.3 g O G04BX15 peramivir 0.6 g P J05AH03 pridinol 6 mg O M03BX03 semaglutide 0.11 mg P A10BJ06 sodium zirconium cyclosilicate 7.5 g O V03AE10 vidarabine 0.7 g P J05AB03

Changes of DDDs ATC level name/INN Previous DDD New DDD ATC code

liraglutide 1.2 mg P 1.5 mg P A10BJ02

555 ATC/DDD classification WHO Drug Information Vol. 32, No. 4, 2018

ATC/DDD classification (final)

The following ATC codes and DDDs were agreed at the meeting of the WHO International Working Group for Drug Statistics Methodology in March 2018.

These are considered as final and will be included in the January 2019 version of the ATC/DDD Index.

New ATC 5th level codes

ATC level name/INN ATC code abemaciclib L01XE50 angiotensin II C01CX09 apalutamide L02BB05 avatrombopag B02BX08 candesartan, amlodipine and hydrochlorothiazide C09DX06 cannabidiol N03AX24 cefpodoxime and beta-lactamase inhibitor J01DD64 copanlisib L01XX61 doravirine J05AG06 edaravone N07XX14 fexinidazole P01CA03 fostamatinib B02BX09 gemigliptin and rosuvastatin A10BH52 hydrogen peroxide D11AX25 ibalizumab J05AX23 lamivudine, tenofovir disoproxil and doravirine J05AR24 leuprorelin and bicalutamide L02AE51 metformin, saxagliptin and dapagliflozin A10BD25 omidenepag S01EX06 prasterone G03XX01 talazoparib L01XX60 telotristat A16AX15 trifarotene D10AD06

556 WHO Drug Information Vol. 32, No. 4, 2018 ATC/DDD classification

New ATC level codes (other than 5th levels):

Other sex hormones and modulators of the genital system G03XX

Change of ATC codes: ATC level name/INN Previous ATC New ATC

dimethyl fumarate N07XX09 L04AX07

Changes of ATC level names Previous New ATC code Angiotensin II antagonists, Angiotensin II receptor blockers (ARBs), C09C plain plain Angiotensin II antagonists, Angiotensin II receptor blockers (ARBs), C09CA plain plain Angiotensin II antagonists, Angiotensin II receptor blockers (ARBs), C09D combinations combinations Angiotensin II antagonists and Angiotensin II receptor blockers (ARBs) C09DA diuretics and diuretics Angiotensin II antagonists and Angiotensin II receptor blockers (ARBs) C09DB calcium channel blockers and calcium channel blockers Angiotensin II antagonists, Angiotensin II receptor blockers (ARBs), C09DX other combinations other combinations combinations potassium (different salts in combination) A12BA30

fluoromethylcholine (18F) fluorocholine (18F) V09IX07

557 ATC/DDD classification WHO Drug Information Vol. 32, No. 4, 2018

New DDDs ATC level name/INN DDD unit Adm.R* ATC code artemether 0.28 g R P01BE02 artesunate 0.28 g R P01BE03 benralizumab 0.54 mg P R03DX10 chenodeoxycholic acid 1 g O A05AA01 cladribine 0.34 mg O L04AA40 dupilumab 21.4 mg P D11AH05 emicizumab 15 mg P B02BX06 ertugliflozin 10 mg O A10BK04 guselkumab 1.79 mg P L04AC16 letermovir 0.48 g O,P J05AX18 ocrelizumab 3.29 mg P L04AA36 patiromer calcium 8.4 g O V03AE09 rolapitant 0.18 g O A04AD14 telotristat 0.75 g O A16AX15 * Administration Route: O = oral; P= parenteral.

Change of DDD ATC level name/INN Previous DDD New DDD ATC code

aprepitant 95 mg O 165 mg O A04AD12 aprepitant1 95 mg P 150 mg P A04AD12 temocillin 2 g P 4 g P J01CA17 vasopressin 4 U P 40 U P H01BA01 (argipressin)

1 refers to fosaprepitant

WHO Collaborating Centre for Drug Statistics Methodology Oslo, November 2018

***

558